In ovarian cancer (OC), Seborova et al54 indicated that downregulation of ABCC4, called the “Multidrug resistance protein 4,” was associated with the best sensitivity to chemotherapy and time to progression. Here, ABCC4 is linked to ovarian carcinoma.